Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker "Olmesartan Medoxomil" Versus "Losartan" in Patients With Mild to Moderate Essential Hypertension

NCT00857285 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00857285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00857285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker "Olmesartan Medoxomil" Versus "Losartan" in Patients With Mild to Moderate Essential Hypertension
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2002
Completion date
September 30, 2003
Enrollment
130 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension